Bath & Body Works: The Sale Catalyst Can't Fix Sliding Sales

Activist investor Barington Capital has taken a fresh stake in Bath & Body Works and is pushing the board to explore a sale, and the stock jumped about 2% to 3% in extended trading on the news. That small pop is worth decoding, because it captures the whole argument around this stock: a deeply discounted retailer with real cash generation that the market treats as a declining asset and an activist believes belongs in private equity hands.

The numbers behind Barington's case are not hard to see. Bath & Body Works trades at a market value of roughly $3.5 billion, yet the company expects to generate on the order of $650 million in free cash flow this fiscal year. On the equity alone that is close to an 18% cash yield, and even on the $6.3 billion enterprise value it is about 10%. The stock yields roughly 4.6% in dividends, sells for about 4.4 times EBITDA, and management has shown it can produce cash almost regardless of the sales picture. Barington, led by James Mitarotonda, wants the board to keep that cash working through aggressive share buybacks and, more ambitiously, to test whether a buyer would pay up for a brand with roughly 1,900 U.S. and Canadian stores and a long record of profitability.

That is the bull case, and it is a real one. What the headline leaves out is why the stock is this cheap in the first place — and that reason is the counterweight every investor here has to weigh.

The cheapness is partly earned

Bath & Body Works is not a growth problem hiding at a bargain price. Sales are shrinking. Second-quarter net sales fell 2.3% year over year to $1.51 billion, management forecast a decline of 2.5% to 4% for the full year, and it called the third quarter "rocky," projecting sales down 2.5% to 5% and adjusted earnings per share of just $0.07 to $0.12. Adjusted full-year earnings are guided to $2.60 to $2.80, down from $3.21 in fiscal 2025 — a falling earnings number, not a stable one repriced cheaply because the market overreacted.

Dig into the current-year earnings and they are even less flattering than they look, because the reported figures are flattered by one-offs. The second quarter included roughly $80 million in tariff refunds; strip those out and adjusted earnings per share would have been $0.31, roughly half the reported $0.62. The year also carries an interchange-fee settlement gain and a tax benefit. Adjust the lens to sustainable earnings power and the multiple the market assigns is less a mystery than a fair reading of a business whose earnings are declining.

Add to that the management churn Barington itself cites. CEO Daniel Heaf, a former Nike executive, took over only last year, replacing Gina Boswell in a leadership shakeup. Mitarotonda blames "serial management changes" over five years for the damage. That is an honest diagnosis of why the multiple is where it is, and it is also a reminder that the operational turn is early and unproven. Heaf's "Consumer First Formula" has produced some encouraging signs — the first direct-sales growth since 2021, sequential improvement in body care — but management acknowledges the business remains pressured and the transformation is in early stages.

What a sale actually has to clear

A sale is not a free option on the cash flow. Since the 2021 spin-off from L Brands, the stock has fallen about 78% and net income has dropped roughly half, and the balance sheet, while cash-generative, carries about $3.4 billion in long-term debt against roughly $794 million of cash. That is a leverage profile a private equity buyer could support given the free cash flow — the LBO math is exactly why Barington thinks there is interest — but it is also the reason a deal would be priced off the depressed earnings, not the headline cash yield.

The most immediate catalyst of a sale is the one that costs nothing: Barington plans to publish a letter to the board in the coming weeks and is weighing board representation, possibly through a proxy contest. That letter, the company's response, and any decision to resume buybacks — the current outlook assumes none — are the near-term proof points. The company says it regularly engages with investors and remains committed to evaluating avenues to enhance value, which is standard language that tells you nothing has been decided.

Here is the honest read. The activist arrival makes Bath & Body Works worth watching because the cheapness is stretched, the cash is real, and a real sale process would end with an offer above the current multiple. But none of that fixes the underlying fact that a buyer would be acquiring a brand whose sales and earnings are still falling, run by a management team that has turned over repeatedly. The 2% to 3% pop is the market pricing the possibility of a deal, not a recovery. For an investor, this is a wait-and-see setup: let Barington's letter force the company to make a concrete choice — a sale process, resumed buybacks, or a defense — before treating the architectural discount as an unlock. The sale story is a genuine catalyst; it is not yet evidence that the decline has reversed.